The pharmacological challenges of treating tuberculosis and HIV coinfections

References

• World Health Organization. Global Tuberculosis Report 2016; 2016.
   Google Scholar
• World Health Organization. Tuberculosis and HIV. [cited 2016 Oct 26]. Available from: http://www.who.int/hiv/topics/tb/about_tb/en/
   Google Scholar
• Gao J, Zheng P, Fu H. Prevalence of TB/HIV co-infection in countries except China: a systematic review and meta-analysis. PLoS One. 2013;8:e64915.
   PubMed Web of Science ®Google Scholar
• Gandhi NR, Shah NS, Andrews JR, et al. HIV coinfection in multidrug- and extensively drug-resistant tuberculosis results in high early mortality. Am J Respir Crit Care Med. 2010;181:80–86.
   PubMed Web of Science ®Google Scholar
• Greenberg SD, Frager D, Suster B, et al. Active pulmonary tuberculosis in patients with AIDS: spectrum of radiographic findings (including a normal appearance). Radiology. 1994;193:115–119.
   PubMed Web of Science ®Google Scholar
• Selwyn PA, Alcabes P, Hartel D, et al. Clinical manifestations and predictors of disease progression in drug users with human immunodeficiency virus infection. N Engl J Med. 1992;327:1697–1703.
   PubMed Web of Science ®Google Scholar
• Kwan CK, Ernst JD. HIV and tuberculosis: a deadly human syndemic. Clin Microbiol Rev. 2011;24:351–376.
   PubMed Web of Science ®Google Scholar
• Havlir DV, Kendall MA, Ive P, et al. Timing of antiretroviral therapy for HIV-1 infection and tuberculosis. N Engl J Med. 2011;365:1482–1491.
   PubMed Web of Science ®Google Scholar
• Abdool Karim SS, Naidoo K, Grobler A, et al. Integration of antiretroviral therapy with tuberculosis treatment. N Engl J Med. 2011;365:1492–1501.
   PubMed Web of Science ®Google Scholar
• Manosuthi W, Kiertiburanakul S, Sungkanuparph S, et al. Efavirenz 600 mg/day versus efavirenz 800 mg/day in HIV-infected patients with tuberculosis receiving rifampicin: 48 weeks results. AIDS. 2006;20:131–132.
   PubMed Web of Science ®Google Scholar
• Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. [cited 2016 June 27]. Available from: http://www.aidsinfo.nih.gov/ContentFiles/Adul- tandAdolescentGL.pdf
   Google Scholar
• Dooley KE, Sayre P, Borland J, et al. Safety, tolerability, and pharmacokinetics of the HIV integrase inhibitor dolutegravir given twice daily with rifampin or once daily with rifabutin: results of a phase 1 study among healthy subjects. J Acquir Immune Defic Syndr. 2013;62:21–27.
   PubMed Web of Science ®Google Scholar
• Farenc C, Doroumian S, Cantalloube C, et al. Rifapentine once-weekly dosing effect on efavirenz, emtricitabine and tenofovir pharmacokinetics [poster P-H1]. Conference on Retroviruses and Opportunistic Infections; Boston, Massachusetts; 2014 Mar 3-6.
   Google Scholar
• Centers for Disease Control Managing drug interactions in the treatment of HIV-related tuberculosis. [cited 2016 May 27. Available from: www.cdc.gov/tb/publications/pdf/tbhiv.pdf
   Google Scholar
• Habtewold A, Makonnen E, Amogne W, et al. Is there a need to increase the dose of efavirenz during concomitant rifampicin-based antituberculosis therapy in sub-Saharan Africa? The HIV-TB pharmagene study. Pharmacogenomics. 2015;16:1047–1064.
   PubMed Web of Science ®Google Scholar
• Ramanathan S, Wang H, Stondell T, et al. Pharmacokinetics and drug interaction profile of cobicistat boosted-EVG with atazanavir, rosuvastatin or rifabutin. 13th International Workshop on Clinical Pharmacology of HIV Therapy. 2012 April 16-18. Barcelona. Abstract: O_03.
   Google Scholar
• Stribild [package insert]. Foster City (CA): Gilead Sciences, Inc.; 2012 Aug.
   Google Scholar
• Smith I. Mycobacterium tuberculosis pathogenesis and molecular determinants of virulence. Clin Microbiol Rev. 2003;16:463–496.
   PubMed Web of Science ®Google Scholar
• Guirado E, Schlesinger LS. Modeling the mycobacterium tuberculosis granuloma - the critical battlefield in host immunity and disease. Front Immunol. 2013;4:98.
   PubMed Web of Science ®Google Scholar
• Lin PL, Flynn JL. Understanding latent tuberculosis: a moving target. J Immunol. 2010;185:15–22.
   PubMed Web of Science ®Google Scholar
• Rosas-Taraco AG, Arce-Mendoza AY, Caballero-Olin G, et al. Mycobacterium tuberculosis upregulates coreceptors CCR5 and CXCR4 while HIV modulates CD14 favoring concurrent infection. AIDS Res Hum Retroviruses. 2006;22:45–51.
   PubMed Web of Science ®Google Scholar
• Swaminathan S, Padmapriyadarsini C, Narendran G. HIV-associated tuberculosis: clinical update. Clin Infect Dis. 2010;50:1377–1386.
   PubMed Web of Science ®Google Scholar
• Jones BE, Young SM, Antoniskis D, et al. Relationship of the manifestations of tuberculosis to CD4 cell counts in patients with human immunodeficiency virus infection. Am Rev Respir Dis. 1993;148:1292–1297.
   PubMed Web of Science ®Google Scholar
• Leeds IL, Magee MJ, Kurbatova EV, et al. Site of extrapulmonary tuberculosis is associated with HIV infection. Clin Infect Dis. 2012;55:75–81.
   PubMed Web of Science ®Google Scholar
• Mendelson M. Diagnosing tuberculosis in HIV-infected patients: challenges and future prospects. Br Med Bull. 2007;81-82:149–165.
   PubMed Web of Science ®Google Scholar
• Venkatesh KK, Swaminathan S, Andrews JR, et al. Tuberculosis and HIV co-infection: screening and treatment strategies. Drugs. 2011;71:1133–1152.
   PubMed Web of Science ®Google Scholar
• Weiner M, Savic RM, Kenzie WR, et al. rifapentine pharmacokinetics and tolerability in children and adults treated once weekly with rifapentine and isoniazid for latent tuberculosis infection. J Pediatric Infect Dis Soc. 2014;3:132–145.
   PubMedGoogle Scholar
• Akolo C, Adetifa I, Shepperd S, et al. Treatment of latent tuberculosis infection in HIV infected persons. Cochrane Database Syst Rev. 2010;(1):CD000171.
   PubMed Web of Science ®Google Scholar
• Mazurek GH, Jereb J, Vernon A, et al. Updated guidelines for using interferon gamma release assays to detect mycobacterium tuberculosis infection - United States, 2010. MMWR Recomm Rep. 2010;59:1–25.
   PubMedGoogle Scholar
• Farhat M, Greenaway C, Pai M, et al. False-positive tuberculin skin tests: what is the absolute effect of BCG and non-tuberculous mycobacteria? Int J Tuberc Lung Dis. 2006;10:1192–1204.
   PubMed Web of Science ®Google Scholar
• Campbell JR, Krot J, Elwood K, et al. A systematic review on TST and IGRA tests used for diagnosis of LTBI in immigrants. Mol Diagn Ther. 2015;19:9–24.
   PubMed Web of Science ®Google Scholar
• Mwinga A, Hosp M, Godfrey-Faussett P, et al. Twice weekly tuberculosis preventive therapy in HIV infection in Zambia. Aids. 1998;12:2447–2457.
   PubMed Web of Science ®Google Scholar
• Whalen CC, Johnson JL, Okwera A, et al.; Uganda-Case Western Reserve University Research Collaboration. A trial of three regimens to prevent tuberculosis in Ugandan adults infected with the human immunodeficiency virus. N Engl J Med. 1997;337:801–808.
   PubMed Web of Science ®Google Scholar
• Bucher HC, Griffith LE, Guyatt GH, et al. Isoniazid prophylaxis for tuberculosis in HIV infection: a meta-analysis of randomized controlled trials. Aids. 1999;13:501–507.
   PubMed Web of Science ®Google Scholar
• Pape JW, Jean SS, Ho JL, et al. Effect of isoniazid prophylaxis on incidence of active tuberculosis and progression of HIV infection. Lancet. 1993;342:268–272.
   PubMed Web of Science ®Google Scholar
• Juhl IU, Christensen BV, Bulow HH, et al. [Quality assurance in postoperative pain treatment]. Ugeskr Laeger. 1994;156:4580–4584.
   PubMedGoogle Scholar
• Ano H, Matsumoto T, Yoshida H, et al. Fluctuation in the ratio between drug-resistant and -susceptible M. tuberculosis bacilli which were isolated from patients with prolonged anti-tuberculosis treatment. Kekkaku. 2003;78:739–746.
   PubMedGoogle Scholar
• Weiner M, Egelund EF, Engle M, et al. Pharmacokinetic interaction of rifapentine and raltegravir in healthy volunteers. J Antimicrob Chemother. 2014;69:1079–1085.
   PubMed Web of Science ®Google Scholar
• Podany AT, Bao Y, Swindells S, et al. Efavirenz pharmacokinetics and pharmacodynamics in HIV-infected persons receiving rifapentine and isoniazid for tuberculosis prevention. Clin Infect Dis. 2015;61:1322–1327.
   PubMed Web of Science ®Google Scholar
• Martinson NA, Barnes GL, Moulton LH, et al. New regimens to prevent tuberculosis in adults with HIV infection. N Engl J Med. 2011;365:11–20.
   PubMed Web of Science ®Google Scholar
• Sterling TR, Villarino ME, Borisov AS, et al. Three months of rifapentine and isoniazid for latent tuberculosis infection. N Engl J Med. 2011;365:2155–2166.
   PubMed Web of Science ®Google Scholar
• O’Donnell MR, Padayatchi N, Kvasnovsky C, et al. Treatment outcomes for extensively drug-resistant tuberculosis and HIV co-infection. Emerg Infect Dis. 2013;19:416–424.
   PubMed Web of Science ®Google Scholar
• Okwera A, Whalen C, Byekwaso F, et al.; The Makerere University-Case Western University Research Collaboration. Randomised trial of thiacetazone and rifampicin-containing regimens for pulmonary tuberculosis in HIV-infected Ugandans. Lancet. 1994;344:1323–1328.
   PubMed Web of Science ®Google Scholar
• Jindani A, Nunn AJ, Enarson DA. Two 8-month regimens of chemotherapy for treatment of newly diagnosed pulmonary tuberculosis: international multicentre randomised trial. Lancet. 2004;364:1244–1251.
   PubMed Web of Science ®Google Scholar
• Khan FA, Minion J, Pai M, et al. Treatment of active tuberculosis in HIV-coinfected patients: a systematic review and meta-analysis. Clin Infect Dis. 2010;50:1288–1299.
   PubMed Web of Science ®Google Scholar
• Maartens G, Decloedt E, Cohen K. Effectiveness and safety of antiretrovirals with rifampicin: crucial issues for high-burden countries. Antivir Ther. 2009;14:1039–1043.
   PubMed Web of Science ®Google Scholar
• Decloedt EH, Maartens G, Smith P, et al. The safety, effectiveness and concentrations of adjusted lopinavir/ritonavir in HIV-infected adults on rifampicin-based antitubercular therapy. PLoS One. 2012;7:e32173.
   PubMed Web of Science ®Google Scholar
• Haas DW, Koletar SL, Laughlin L, et al. Hepatotoxicity and gastrointestinal intolerance when healthy volunteers taking rifampin add twice-daily atazanavir and ritonavir. J Acquir Immune Defic Syndr. 2009;50:290–293.
   PubMed Web of Science ®Google Scholar
• Nijland HM, R F L, Rongen GA, et al. High incidence of adverse events in healthy volunteers receiving rifampicin and adjusted doses of lopinavir/ritonavir tablets. Aids. 2008;22:931–935.
   PubMed Web of Science ®Google Scholar
• Schmitt C, Riek M, Winters K, et al. Unexpected hepatotoxicity of rifampin and saquinavir/ritonavir in healthy male volunteers. Arch Drug Inf. 2009;2:8–16.
   PubMedGoogle Scholar
• Decloedt EH, McIlleron H, Smith P, et al. Pharmacokinetics of lopinavir in HIV-infected adults receiving rifampin with adjusted doses of lopinavir-ritonavir tablets. Antimicrob Agents Chemother. 2011;55:3195–3200.
   PubMed Web of Science ®Google Scholar
• Losso MH, Lourtau LD, Toibaro JJ, et al. The use of saquinavir/ritonavir 1000/100 mg twice daily in patients with tuberculosis receiving rifampin. Antivir Ther. 2004;9:1031–1033.
   PubMed Web of Science ®Google Scholar
• McIlleron H, Ren Y, Nuttall J, et al. Lopinavir exposure is insufficient in children given double doses of lopinavir/ritonavir during rifampicin-based treatment for tuberculosis. Antivir Ther. 2011;16:417–421.
   PubMed Web of Science ®Google Scholar
• Ren Y, Nuttall JJ, Egbers C, et al. Effect of rifampicin on lopinavir pharmacokinetics in HIV-infected children with tuberculosis. J Acquir Immune Defic Syndr. 2008;47:566–569.
   PubMed Web of Science ®Google Scholar
• Ogburn ET, Jones DR, Masters AR, et al. Efavirenz primary and secondary metabolism in vitro and in vivo: identification of novel metabolic pathways and cytochrome P450 2A6 as the principal catalyst of efavirenz 7-hydroxylation. Drug Metab Dispos. 2010;38:1218–1229.
   PubMed Web of Science ®Google Scholar
• Lindfelt T, O’Brien J, Song JC, et al. Efavirenz plasma concentrations and cytochrome 2B6 polymorphisms. Ann Pharmacother. 2010;44:1572–1578.
   PubMed Web of Science ®Google Scholar
• Marzolini C, Telenti A, Decosterd LA, et al. Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients. Aids. 2001;15:71–75.
   PubMed Web of Science ®Google Scholar
• Liu J, Chan-Tack KM, Jadhav P, et al. Why did the FDA approve efavirenz 800 mg when co-administered with rifampin? Int J Clin Pharmacol Ther. 2014;52:446–453.
   PubMed Web of Science ®Google Scholar
• Boulle A, van Cutsem G, Cohen K, et al. Outcomes of nevirapine- and efavirenz-based antiretroviral therapy when coadministered with rifampicin-based antitubercular therapy. Jama. 2008;300:530–539.
   PubMed Web of Science ®Google Scholar
• Brennan-Benson P, Lyus R, Harrison T, et al. Pharmacokinetic interactions between efavirenz and rifampicin in the treatment of HIV and tuberculosis: one size does not fit all. Aids. 2005;19:1541–1543.
   PubMed Web of Science ®Google Scholar
• Tsuchiya K, Gatanaga H, Tachikawa N, et al. Homozygous CYP2B6 *6 (Q172H and K262R) correlates with high plasma efavirenz concentrations in HIV-1 patients treated with standard efavirenz-containing regimens. Biochem Biophys Res Commun. 2004;319:1322–1326.
   PubMed Web of Science ®Google Scholar
• Gounden V, van Niekerk C, Snyman T, et al. Presence of the CYP2B6 516G> T polymorphism, increased plasma Efavirenz concentrations and early neuropsychiatric side effects in South African HIV-infected patients. AIDS Res Ther. 2010;7:32.
   PubMed Web of Science ®Google Scholar
• Manosuthi W, Sungkanuparph S, Tantanathip P, et al. Body weight cutoff for daily dosage of efavirenz and 60-week efficacy of efavirenz-based regimen in human immunodeficiency virus and tuberculosis coinfected patients receiving rifampin. Antimicrob Agents Chemother. 2009;53:4545–4548.
   PubMed Web of Science ®Google Scholar
• Ribera E, Pou L, Lopez RM, et al. Pharmacokinetic interaction between nevirapine and rifampicin in HIV-infected patients with tuberculosis. J Acquir Immune Defic Syndr. 2001;28:450–453.
   PubMed Web of Science ®Google Scholar
• Autar RS, Wit FW, Sankote J, et al. Nevirapine plasma concentrations and concomitant use of rifampin in patients coinfected with HIV-1 and tuberculosis. Antivir Ther. 2005;10:937–943.
   PubMed Web of Science ®Google Scholar
• Avihingsanon A, Manosuthi W, Kantipong P, et al. Pharmacokinetics and 48-week efficacy of nevirapine: 400 mg versus 600 mg per day in HIV-tuberculosis coinfection receiving rifampicin. Antivir Ther. 2008;13:529–536.
   PubMed Web of Science ®Google Scholar
• Sulkowski MS, Thomas DL, Mehta SH, et al. Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: role of hepatitis C and B infections. Hepatology. 2002;35:182–189.
   PubMed Web of Science ®Google Scholar
• Borin MT, Chambers JH, Carel BJ, et al. Pharmacokinetic study of the interaction between rifabutin and delavirdine mesylate in HIV-1 infected patients. Antiviral Res. 1997;35:53–63.
   PubMed Web of Science ®Google Scholar
• Crauwels H, van Heeswijk RP, Stevens M, et al. Clinical perspective on drug-drug interactions with the non-nucleoside reverse transcriptase inhibitor rilpivirine. AIDS Rev. 2013;15:87–101.
   PubMed Web of Science ®Google Scholar
• Gagliardini R, Fabbiani M, Fortuna S, et al. Pharmacokinetics of etravirine in HIV-infected patients concomitantly treated with rifampin for tuberculosis. Infection. 2014;42:775–778.
   PubMed Web of Science ®Google Scholar
• Wenning LA, Hanley WD, Brainard DM, et al. Effect of rifampin, a potent inducer of drug-metabolizing enzymes, on the pharmacokinetics of raltegravir. Antimicrob Agents Chemother. 2009;53:2852–2856.
   PubMed Web of Science ®Google Scholar
• Grinsztejn B, de Castro N, Arnold V, et al. Raltegravir for the treatment of patients co-infected with HIV and tuberculosis (ANRS 12 180 Reflate TB): a multicentre, phase 2, non-comparative, open-label, randomised trial. Lancet Infect Dis. 2014;14:459–467.
   PubMed Web of Science ®Google Scholar
• Klis S, Daskapan A, Akkerman OW, et al. Raltegravir and rifampicin in patients with HIV and tuberculosis. Lancet Infect Dis. 2014;14:1046–1047.
   PubMed Web of Science ®Google Scholar
• Fortuna S, Fabbiani M, Digiambenedetto S, et al. Variability of raltegravir plasma levels in the clinical setting. Pharmacology. 2013;92:43–48.
   PubMed Web of Science ®Google Scholar
• Song I, Borland J, Chen S, et al. Effect of atazanavir and atazanavir/ritonavir on the pharmacokinetics of the next-generation HIV integrase inhibitor, S/GSK1349572. Br J Clin Pharmacol. 2011;72:103–108.
   PubMed Web of Science ®Google Scholar
• Kakuda TN, Scholler-Gyure M, Hoetelmans RM. Pharmacokinetic interactions between etravirine and non-antiretroviral drugs. Clin Pharmacokinet. 2011;50:25–39.
   PubMed Web of Science ®Google Scholar
• Burman WJ, Gallicano K, Peloquin C. Comparative pharmacokinetics and pharmacodynamics of the rifamycin antibacterials. Clin Pharmacokinet. 2001;40:327–341.
   PubMed Web of Science ®Google Scholar
• Jenks JD, Kumarasamy N, Ezhilarasi C, et al. Improved tuberculosis outcomes with daily vs. intermittent rifabutin in HIV-TB coinfected patients in India. Int J Tuberc Lung Dis. 2016;20:1181–1184.
   PubMed Web of Science ®Google Scholar
• Weiner M, Benator D, Burman W, et al. Association between acquired rifamycin resistance and the pharmacokinetics of rifabutin and isoniazid among patients with HIV and tuberculosis. Clin Infect Dis. 2005;40:1481–1491.
   PubMed Web of Science ®Google Scholar
• Burman W, Benator D, Vernon A, et al. Acquired rifamycin resistance with twice-weekly treatment of HIV-related tuberculosis. Am J Respir Crit Care Med. 2006;173:350–356.
   PubMed Web of Science ®Google Scholar
• Weiner M, Benator D, Peloquin CA, et al. Evaluation of the drug interaction between rifabutin and efavirenz in patients with HIV infection and tuberculosis. Clin Infect Dis. 2005;41:1343–1349.
   PubMed Web of Science ®Google Scholar
• Priftin [package insert]. In: Sanofi-Aventis, ed. Bridgewater (NJ); 2014.
   Google Scholar
• Prats E, Carril J, Herranz R, et al. [A Spanish multicenter scintigraphic study of the breast using Tc 99m MIBI. Report of results]. Rev Esp Med Nucl. 1998;17:338–350.
   PubMedGoogle Scholar
• Brainard DM, Kassahun K, Wenning LA, et al. Lack of a clinically meaningful pharmacokinetic effect of rifabutin on raltegravir: in vitro/in vivo correlation. J Clin Pharmacol. 2011;51:943–950.
   PubMed Web of Science ®Google Scholar
• Juarez-Reyes M, Gallivan M, Chyorny A, et al. Completion rate and side-effect profile of three-month isoniazid and rifapentine treatment for latent tuberculosis infection in an urban county jail. Open Forum Infect Dis. 2016;3:ofv220.
   PubMed Web of Science ®Google Scholar
• Dorman SE, Goldberg S, Stout JE, et al. Substitution of rifapentine for rifampin during intensive phase treatment of pulmonary tuberculosis: study 29 of the tuberculosis trials consortium. J Infect Dis. 2012;206:1030–1040.
   PubMed Web of Science ®Google Scholar
• Cohn DL. Treatment of latent tuberculosis infection. Semin Respir Infect. 2003;18:249–262.
   PubMedGoogle Scholar
• Mfinanga SG, Kirenga BJ, Chanda DM, et al. Early versus delayed initiation of highly active antiretroviral therapy for HIV-positive adults with newly diagnosed pulmonary tuberculosis (TB-HAART): a prospective, international, randomised, placebo-controlled trial. Lancet Infect Dis. 2014;14:563–571.
   PubMed Web of Science ®Google Scholar
• Lai RP, Meintjes G, Wilkinson RJ. HIV-1 tuberculosis-associated immune reconstitution inflammatory syndrome. Semin Immunopathol. 2016;38:185–198.
   PubMed Web of Science ®Google Scholar
• Meintjes G, Rabie H, Wilkinson RJ, et al. Tuberculosis-associated immune reconstitution inflammatory syndrome and unmasking of tuberculosis by antiretroviral therapy. Clin Chest Med. 2009;30:797–810.
   PubMed Web of Science ®Google Scholar
• Leone S, Nicastri E, Giglio S, et al. Immune reconstitution inflammatory syndrome associated with Mycobacterium tuberculosis infection: a systematic review. Int J Infect Dis. 2010;14:e283–291.
   PubMed Web of Science ®Google Scholar
• Garci J, Perkins A, Garau M, et al. [Successful treatment with voriconazol of a Pseudallescheria boydii fungus ball in a HIV positive patient and previous tuberculosis]. Rev Iberoam Micol. 2003;20:64–67.
   PubMedGoogle Scholar
• Naidoo K, Yende-Zuma N, Padayatchi N, et al. The immune reconstitution inflammatory syndrome after antiretroviral therapy initiation in patients with tuberculosis: findings from the SAPiT trial. Ann Intern Med. 2012;157:313–324.
   PubMed Web of Science ®Google Scholar
• Blanc FX, Sok T, Laureillard D, et al. Earlier versus later start of antiretroviral therapy in HIV-infected adults with tuberculosis. N Engl J Med. 2011;365:1471–1481.
   PubMed Web of Science ®Google Scholar
• Yee D, Valiquette C, Pelletier M, et al. Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis. Am J Respir Crit Care Med. 2003;167:1472–1477.
   PubMed Web of Science ®Google Scholar
• Perriens JH, St Louis ME, Mukadi YB, et al. Pulmonary tuberculosis in HIV-infected patients in Zaire. A controlled trial of treatment for either 6 or 12 months. N Engl J Med. 1995;332:779–784.
   PubMed Web of Science ®Google Scholar
• McIlleron H, Meintjes G, Burman WJ, et al. Complications of antiretroviral therapy in patients with tuberculosis: drug interactions, toxicity, and immune reconstitution inflammatory syndrome. J Infect Dis. 2007;196(Suppl 1):S63–75.
   PubMed Web of Science ®Google Scholar
• Shu CC, Lee CH, Lee MC, et al. Hepatotoxicity due to first-line anti-tuberculosis drugs: a five-year experience in a Taiwan medical centre. Int J Tuberc Lung Dis. 2013;17:934–939.
   PubMed Web of Science ®Google Scholar
• La Porte CJ, Colbers EP, Bertz R, et al. Pharmacokinetics of adjusted-dose lopinavir-ritonavir combined with rifampin in healthy volunteers. Antimicrob Agents Chemother. 2004;48:1553–1560.
   PubMed Web of Science ®Google Scholar
• Yimer G, Ueda N, Habtewold A, et al. Pharmacogenetic & pharmacokinetic biomarker for efavirenz based ARV and rifampicin based anti-TB drug induced liver injury in TB-HIV infected patients. PLoS One. 2011;6:e27810.
   PubMed Web of Science ®Google Scholar
• Sharma SK, Singla R, Sarda P, et al. Safety of 3 different reintroduction regimens of antituberculosis drugs after development of antituberculosis treatment-induced hepatotoxicity. Clin Infect Dis. 2010;50:833–839.
   PubMed Web of Science ®Google Scholar
• Chang KC, Leung CC. The best approach to reintroducing tuberculosis treatment after hepatotoxicity is still open to debate. Clin Infect Dis. 2010;51:366–367. author reply 367-368.
   PubMed Web of Science ®Google Scholar
• Chang KC, Leung CC, Yew WW, et al. Hepatotoxicity of pyrazinamide: cohort and case-control analyses. Am J Respir Crit Care Med. 2008;177:1391–1396.
   PubMed Web of Science ®Google Scholar
• Saukkonen JJ, Cohn DL, Jasmer RM, et al. An official ATS statement: hepatotoxicity of antituberculosis therapy. Am J Respir Crit Care Med. 2006;174:935–952.
   PubMed Web of Science ®Google Scholar
• McIlleron H, Abdel-Rahman S, Dave JA, et al. Special populations and pharmacogenetic issues in tuberculosis drug development and clinical research. J Infect Dis. 2015;211(Suppl 3):S115S125.
   Web of Science ®Google Scholar
• Peloquin CA, Nitta AT, Burman WJ, et al. Low antituberculosis drug concentrations in patients with AIDS. Ann Pharmacother. 1996;30:919–925.
   PubMed Web of Science ®Google Scholar
• Gurumurthy P, Ramachandran G, Hemanth Kumar AK, et al. Decreased bioavailability of rifampin and other antituberculosis drugs in patients with advanced human immunodeficiency virus disease. Antimicrob Agents Chemother. 2004;48:4473–4475.
   PubMed Web of Science ®Google Scholar
• Gurumurthy P, Ramachandran G, Hemanth Kumar AK, et al. Malabsorption of rifampin and isoniazid in HIV-infected patients with and without tuberculosis. Clin Infect Dis. 2004;38:280–283.
   PubMed Web of Science ®Google Scholar
• Sahai J, Gallicano K, Swick L, et al. Reduced plasma concentrations of antituberculosis drugs in patients with HIV infection. Ann Intern Med. 1997;127:289–293.
   PubMed Web of Science ®Google Scholar
• Holland DP, Hamilton CD, Weintrob AC, et al. Therapeutic drug monitoring of antimycobacterial drugs in patients with both tuberculosis and advanced human immunodeficiency virus infection. Pharmacotherapy. 2009;29:503–510.
   PubMed Web of Science ®Google Scholar
• Chideya S, Winston CA, Peloquin CA, et al. Isoniazid, rifampin, ethambutol, and pyrazinamide pharmacokinetics and treatment outcomes among a predominantly HIV-infected cohort of adults with tuberculosis from Botswana. Clin Infect Dis. 2009;48:1685–1694.
   PubMed Web of Science ®Google Scholar
• Weiner M, Burman W, Vernon A, et al. Low isoniazid concentrations and outcome of tuberculosis treatment with once-weekly isoniazid and rifapentine. Am J Respir Crit Care Med. 2003;167:1341–1347.
   PubMed Web of Science ®Google Scholar
• Prahl JB, Johansen IS, Cohen AS, et al. Clinical significance of 2 h plasma concentrations of first-line anti-tuberculosis drugs: a prospective observational study. J Antimicrob Chemother. 2014;69:2841–2847.
   PubMed Web of Science ®Google Scholar
• Vernon A, Burman W, Benator D, et al. Acquired rifamycin monoresistance in patients with HIV-related tuberculosis treated with once-weekly rifapentine and isoniazid. Tuberculosis trials consortium. Lancet. 1999;353:1843–1847.
   PubMed Web of Science ®Google Scholar
• Li J, Munsiff SS, Driver CR, et al. Relapse and acquired rifampin resistance in HIV-infected patients with tuberculosis treated with rifampin- or rifabutin-based regimens in New York City, 1997-2000. Clin Infect Dis. 2005;41:83–91.
   PubMed Web of Science ®Google Scholar
• Venturini E, Turkova A, Chiappini E, et al. Tuberculosis and HIV co-infection in children. BMC Infect Dis. 2014;14(Suppl 1):S5.
   PubMed Web of Science ®Google Scholar
• Parsons TL, Marzinke MA, Hoang T, et al. Quantification of rifapentine, a potent antituberculosis drug, from dried blood spot samples using liquid chromatographic-tandem mass spectrometric analysis. Antimicrob Agents Chemother. 2014;58:6747–6757.
   PubMed Web of Science ®Google Scholar
• Loeliger A, Suthar AB, Ripin D, et al. Protease inhibitor-containing antiretroviral treatment and tuberculosis: can rifabutin fill the breach?. Int J Tuberc Lung Dis. 2012;16:6–15.
   PubMed Web of Science ®Google Scholar
• Beer L, Skarbinski J. Adherence to antiretroviral therapy among HIV-infected adults in the United States. AIDS Educ Prev. 2014;26:521–537.
   PubMed Web of Science ®Google Scholar
• Lawn SD, Churchyard G. Epidemiology of HIV-associated tuberculosis. Curr Opin HIV AIDS. 2009;4:325–333.
   PubMed Web of Science ®Google Scholar
• Cohen J. South Africa’s bid to end AIDS. Science. 2016;353:18–21.
   PubMed Web of Science ®Google Scholar
• Gaolathe T, Wirth KE, Holme MP, et al. Botswana’s progress toward achieving the 2020 UNAIDS 90-90-90 antiretroviral therapy and virological suppression goals: a population-based survey. Lancet HIV. 2016;3:e221–230.
   PubMed Web of Science ®Google Scholar